Since chronic lymphocytic leukemia usually progresses slowly, many patients will not need treatment for a significant length of time, sometimes for decades. However, in the case of chronic lymphocytic leukemia that is progressing rapidly, early treatment is needed.
Treatments for chronic lymphocytic leukemia may include watchful waiting, radiation therapy, chemotherapy, targeted therapy, immunotherapy (biotherapy or biologics), chemotherapy combined with bone marrow transplant (stem cell transplant), and leukapheresis (cell reduction).
Watchful waiting (Stage 0) – Watchful waiting involves observing a patient with early chronic lymphocytic leukemia who is usually without symptoms (asymptomatic) for the appearance of any symptoms or a change in their condition.
Radiation therapy – Radiation therapy uses intense, directed X-rays, protons, or other types of radiation to stop cancer cells from growing or to kill cancer cells.
Chemotherapy – Chemotherapy (with or without steroids) uses drugs that can be administered either orally or intravenously (systemic chemotherapy; IV).
Targeted therapy – Targeted therapy uses drugs that are designed to attack certain characteristics in cancer cells. Types of targeted therapies used to treat chronic lymphocytic leukemia include tyrosine kinase inhibitors (TKIs), BLC2 inhibitor therapy, and monoclonal antibody therapy.
Tyrosine kinase inhibitors (TKIs) –Tyrosine kinase inhibitors stop tumors from growing, and include the targeted therapy drugs, ibrutinib, idelalisib, and duvelisib, for the treatment of chronic lymphocytic leukemia.
BCL2 inhibitor therapy – BCL2 therapy blocks a protein on leukemia cells, allowing them to become more receptive to anticancer drugs, and includes the drug, Venetoclax, for the treatment of chronic lymphocytic leukemia.
Monoclonal antibody therapy – Monoclonal antibody therapy is made from antibodies grown in the laboratory from an immune system cell that can stop cancer cells from growing, stop cancer cells from spreading, or kill cancer cells, and includes the drugs rituximab, ofatumumab, and Obinutuzumab, either alone or in combination with chemotherapy, to treat symptomatic or progressive chronic lymphocytic leukemia.
Immunotherapy (Biotherapy or Biologic Therapy) – Immunotherapy uses the patient’s immune system to increase, control, or reset the body’s natural immunity to fight cancer. Types of immunotherapy include immunomodulating agents and CAR T-Cell Therapy.
Immunomodulating agents – Immunomodulating agents increase the ability of the body’s T cells (immune cells) to kill leukemia, and include the drug, lenalidomide, which can be used either alone or in combination with rituximab for patients with symptomatic or progressive chronic lymphocytic leukemia.
CAR T-Cell Therapy – Car T-cell therapy is a type of immunotherapy that alters T cells, so that they can attack cancer cells. The T cells are first extracted from the patient and altered in a laboratory, and then returned to the patient via infusion. The CAR T cells then increase in the blood, kill the leukemia cells, and are used in the treatment of symptomatic or progressive chronic lymphocytic leukemia.
Chemotherapy with Bone Marrow Transplant (Stem Cell Transplant) – This treatment first uses chemotherapy to destroy leukemia cells, and then stem cells extracted from either the blood or bone marrow are returned to the patient via infusion. The new stem cells grow into healthy blood cells.
Leukapheresis – This treatment lowers the number of excessive cells in chronic lymphocytic leukemia that may interfere with circulation and can be given before or after chemotherapy.
Clinical trials – Some patients may also want to enroll in clinical trials to gain access to new, experimental treatments for chronic lymphocytic leukemia.
Treatments for chronic lymphocytic leukemia may include watchful waiting, radiation therapy, chemotherapy, targeted therapy, immunotherapy (biotherapy or biologics), chemotherapy combined with bone marrow transplant (stem cell transplant), and leukapheresis (cell reduction).
Green tea extract in pill form is an alternative treatment that has demonstrated some effectiveness for treating early chronic lymphocytic leukemia by killing leukemia cells with its compound EGCG; however, more study is needed.